Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study [Yahoo! Finance]
Radiopharm Theranostics Limited - American Depositary Shares (RADX)
Company Research
Source: Yahoo! Finance
endpoint for RAD101 imaging of suspected post-treatment brain metastases; enrollment is nearly complete and official study results are expected in May–June with planned FDA discussions on Phase III design in mid-2026. Diagnostic value : RAD101 is a small-molecule PET tracer targeting fatty acid synthase designed to help distinguish tumor recurrence from radiation necrosis when MRI is equivocal, and presenters cited biopsy-confirmed PET-positive cases that supported its clinical utility. Development and commercial outlook: Radiopharm aims to be ready to start a registrational Phase III (estimated ~150–200 patients) before the end of 2026, has received business development interest, and referenced an external U.S. sales potential of more than $500 million annually. Interested in Radiopharm Theranostics Limited - Sponsored ADR? Here are five stocks we like better. Radiopharm Theranostics (NASDAQ:RADX) executives and clinical investigators highlighted new interim findings from the
Show less
Read more
Impact Snapshot
Event Time:
RADX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RADX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RADX alerts
High impacting Radiopharm Theranostics Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
RADX
News
- Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate CancerGlobeNewswire
- Radiopharm Theranostics Highlights 90% Positive RAD101 Interim Data, Eyes Phase III FDA Talks [Yahoo! Finance]Yahoo! Finance
- Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain MetastasesGlobeNewswire
- Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)GlobeNewswire
- RADX Fiscal 1H:26 Activity and Cash Flows [Yahoo! Finance]Yahoo! Finance
RADX
Sec Filings
- 4/1/26 - Form 3
- 4/1/26 - Form 3
- 3/31/26 - Form 3
- RADX's page on the SEC website